Telehealth firm LifeMD said on Tuesday it would partner with Novo Nordisk to offer its diabetes drug Ozempic at $499 per ...

Alibaba, which has been gaining traction in AI demands, was up 4.7%, while Tilray, a pharmaceutical company, soared 60.9% ...

Morgan Stanley has downgraded Novo Nordisk, whose U.S. shares are already down a third this year. That downgrade forecasts ...

Monday's downgrading entity was white-shoe investment bank Morgan Stanley, whose analyst Thibault Boutherin felt compelled to ...

Novo Nordisk stock fell after Morgan Stanley said Ozempic and Wegovy prescription growth is stagnating, and recommended ...

LifeMD (LFMD) stock is in focus as the firm expands its telehealth collaboration with Novo Nordisk to offer the pharma ...

I N recent months makers of weight-loss drugs have gone on a crash diet. In late July Novo Nordisk, the Danish firm that gave ...

Morgan Stanley analyst Thibault Boutherin pointed to slowing momentum in U.S. prescriptions for Novo's flagship GLP-1 drugs, ...

Danish drugmaker Novo Nordisk's India Head, Vikrant Shrotiya, shares that the pharmaceutical giant is ready to launch Ozempic ...

Ozempic has been approved in India for type 2 diabetes. The blockbuster drug by Danish drugmaker Novo Nordisk has taken the ...

Novo Nordisk confirms the upcoming India launch of Ozempic, its once-weekly semaglutide injection for Type 2 diabetes and ...

LifeMD’s telehealth platform is seamlessly integrated with NovoCare ® Pharmacy to provide easy, reliable access to Novo Nordisk’s FDA-approved GLP-1 medications, Ozempic ® and Wegovy ®, at the most ...